ADx

Drug Profile

ADx

Latest Information Update: 10 Jun 2016

Price : $50

At a glance

  • Originator Alzeca Biosciences
  • Class Antidementias; Contrast media; Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 08 Jun 2016 Preclinical trials in Alzheimer's disease (Diagnosis) in USA before June 2016
  • 08 Jun 2016 Alzeca Biosciences plans a clinical trial for diagnosis of Alzheimer's disease
  • 10 May 2016 Early research in Alzheimer's disease (Diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top